In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Idenix partners HIV candidate, other NNRTIs with GSK; terminated

Executive Summary

Idenix Pharmaceuticals (public infectious disease company majority owned by Novartis) has licensed GlaxoSmithKline exclusive worldwide rights to develop, manufacture, and sell a group of its non-nucleoside reverse transcriptase inhibitors (NNRTIs) including once-daily IDX899, in Phase II for HIV and AIDS.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register